Your browser doesn't support javascript.
loading
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca, Paula; Carmona-Bayonas, Alberto; Lamarca, Angela; Barriuso, Jorge; Castaño, Angel; Benavent, Marta; Alonso, Vicente; Riesco, Maria Del Carmen; Alonso-Gordoa, Teresa; Custodio, Ana; Sanchez Canovas, Manuel; Hernando, Jorge; López, Carlos; La Casta, Adelaida; Fernandez Montes, Ana; Marazuela, Mónica; Crespo, Guillermo; Diaz, Jose Angel; Feliciangeli, Eduardo; Gallego, Javier; Llanos, Marta; Segura, Angel; Vilardell, Felip; Percovich, Juan Carlos; Grande, Enrique; Capdevila, Jaume; Valle, Juan; Garcia-Carbonero, Rocio.
Afiliación
  • Jimenez-Fonseca P; Medical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain.
  • Carmona-Bayonas A; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain.
  • Lamarca A; Medical Oncology Department, The Christie NHS Foundation Trust, ENETS Centre of Excellence, Manchester, United Kingdom.
  • Barriuso J; Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, United Kingdom.
  • Castaño A; Medical Oncology Department, The Christie NHS Foundation Trust, ENETS Centre of Excellence, Manchester, United Kingdom.
  • Benavent M; Division of Cancer Sciences, Faculty of Biology Medicine and Health, University of Manchester, Manchester, United Kingdom.
  • Alonso V; Pathology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
  • Riesco MDC; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Sevilla, Spain.
  • Alonso-Gordoa T; Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Custodio A; Medical Oncology Department, Hospital Universitario Doce de Octubre, IIS imas12, UCM, CNIO, CIBERONC, Madrid, Spain.
  • Sanchez Canovas M; Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Hernando J; Medical Oncology Department, Hospital Universitario La Paz, CIBERONC CB16/12/00398, Madrid, Spain.
  • López C; Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain.
  • La Casta A; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall Hebron Institute of Oncology (VHIO), Autonomous University of Barcelona, Barcelona, Spain.
  • Fernandez Montes A; Medical Oncology Department, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.
  • Marazuela M; Medical Oncology Department, Hospital Universitario Donostia, San Sebastián, Spain.
  • Crespo G; Medical Oncology Department, Complexo Hospitalario Universitario de Ourense, Ourense, Spain.
  • Diaz JA; Endocrinology Department, Hospital Universitario de la Princesa, Madrid, Spain.
  • Feliciangeli E; Medical Oncology Department, Complejo Asistencial Universitario de Burgos, Burgos, Spain.
  • Gallego J; Endocrinology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain.
  • Llanos M; Medical Oncology Department, Hospital Universitario Santa Lucia, Cartagena, Spain.
  • Segura A; Medical Oncology Department, Hospital General Universitario de Elche, Elche, Spain.
  • Vilardell F; Medical Oncology Department, Hospital Universitario de Canarias, Universidad de La Laguna, Tenerife, Spain.
  • Percovich JC; Medical Oncology Department, Hospital Universitario La Fe, Valencia, Spain.
  • Grande E; Pathology Department, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
  • Capdevila J; Endocrinology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain.
  • Valle J; Medical Oncology Department, MD Anderson Cancer Center Madrid, Madrid, Spain.
  • Garcia-Carbonero R; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Vall Hebron Institute of Oncology (VHIO), Autonomous University of Barcelona, Barcelona, Spain.
Neuroendocrinology ; 112(1): 88-100, 2022.
Article en En | MEDLINE | ID: mdl-33508849
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Péptidos Cíclicos / Neoplasias Gástricas / Somatostatina / Octreótido / Ensayos Clínicos Controlados Aleatorios como Asunto / Sistema de Registros / Tumores Neuroendocrinos / Antineoplásicos Hormonales / Supervivencia sin Progresión Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Neuroendocrinology Año: 2022 Tipo del documento: Article País de afiliación: España
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Péptidos Cíclicos / Neoplasias Gástricas / Somatostatina / Octreótido / Ensayos Clínicos Controlados Aleatorios como Asunto / Sistema de Registros / Tumores Neuroendocrinos / Antineoplásicos Hormonales / Supervivencia sin Progresión Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Neuroendocrinology Año: 2022 Tipo del documento: Article País de afiliación: España